13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001773195
Total reported value
$2.2B
$2.2B
103 檔
22.6%
As reported in its official Q1 2026 Form 13F filing, Affinity Asset Advisors, LLC's tracked investment portfolio stood at $2.2B with 103 total positions.
In Q1 2026, Affinity Asset Advisors, LLC displayed an active expansion posture, initiating 26 new positions and adding to 31 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 6.72% | -6.72% | EXIT | |
| 2 | APGE | Apogee Therapeutics Inc | Stock-Other | 5.59% | +0.33% | +4.05% | |
| 3 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 5.03% | -0.68% | +34.00% | |
| 4 | ERAS | Erasca Inc | Stock-Other | 4.47% | -0.12% | +37.18% | |
| 5 | INSM | Insmed Inc | Stock-Healthcare | 4.05% | -0.92% | +6.67% | |
| 6 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 4.01% | +1.99% | +64.71% | |
| 7 | SYRE | Spyre Therapeutics Inc | Stock-Other | 3.33% | +1.80% | -10.71% | |
| 8 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.87% | -2.87% | EXIT | |
| 9 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.83% | -0.03% | -8.11% | |
| 10 | ANAB | Anaptysbio Inc | Stock-Other | 2.69% | -0.17% | +111.38% | |
| 11 | ALKS | Alkermes plc | Stock-Healthcare | 2.47% | +0.79% | +35.00% | |
| 12 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.38% | -0.26% | -12.44% | |
| 13 | ABVX | Abivax Sa-adr | Stock-Other | 2.33% | -0.34% | -19.80% | |
| 14 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 2.18% | -1.61% | — | |
| 15 | ACLXGBX | Arcellx Inc | Stock-Other | 2.15% | -2.15% | EXIT | |
| 16 | MRNA | Moderna Inc | Stock-Healthcare | 2.10% | +0.99% | — | |
| 17 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.73% | +0.03% | +247.83% | |
| 18 | NUVL | Nuvalent Inc-a | Stock-Other | 1.59% | -0.05% | -7.02% | |
| 19 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.53% | -1.53% | EXIT | |
| 20 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 1.50% | -0.28% | +57.82% | |
| 21 | COGT | Cogent Biosciences Inc | Stock-Other | 1.49% | -0.70% | +114.29% | |
| 22 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.49% | -0.52% | +76.67% | |
| 23 | STRO | Sutro Biopharma Inc | Stock-Other | 1.38% | +0.38% | +42.91% | |
| 24 | FBRX | Forte Biosciences Inc | Stock-Other | 1.35% | -0.25% | — | |
| 25 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.27% | +1.27% | -37.72% | |
| 26 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.23% | +0.29% | -6.98% | |
| 27 | OVID | Ovid Therapeutics Inc | Stock-Other | 1.22% | +0.01% | +48.76% | |
| 28 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.19% | -0.04% | — | |
| 29 | ASND | Ascendis Pharma A/S | Stock-Other | 1.12% | -1.12% | EXIT | |
| 30 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.05% | -0.14% | +2.74% | |
| 31 | AVTX | Avalo Therapeutics Inc | Stock-Other | 1.03% | +1.39% | +27.57% | |
| 32 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.00% | +1.12% | +100.00% | |
| 33 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 0.94% | -0.94% | EXIT | |
| 34 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.94% | +0.01% | — | |
| 35 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.82% | +0.36% | +42.86% | |
| 36 | ✓ | Zura Bio LTD | Stock-Other | 0.79% | -0.40% | +41.39% | |
| 37 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.77% | +0.29% | — | |
| 38 | SVRA | Savara Inc | Stock-Other | 0.71% | -0.01% | -10.19% | |
| 39 | OMER 9.5 06-15-29Bond | Omeros CORP | Bond | 0.68% | -0.13% | — | |
| 40 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.68% | -0.03% | +954.86% | |
| 41 | ✓ | Helix Acquisition CORP Iii | Stock-Other | 0.66% | -0.06% | — | |
| 42 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.65% | -0.10% | +185.71% | |
| 43 | DMRA | Damora Therapeutics Inc | Stock-Other | 0.60% | -0.10% | — | |
| 44 | EPRX | Eupraxia Pharmaceuticals Inc | Stock-Other | 0.59% | -0.10% | +429.67% | |
| 45 | ANRO | Alto Neuroscience Inc | Stock-Other | 0.58% | +0.43% | — | |
| 46 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.58% | -0.58% | EXIT | |
| 47 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.57% | +0.15% | -59.56% | |
| 48 | BLTE | Belite Bio Inc - Adr | Stock-Other | 0.54% | +0.61% | +225.00% | |
| 49 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.52% | -0.52% | EXIT | |
| 50 | VERA | Vera Therapeutics Inc | Stock-Other | 0.52% | -0.04% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ERAS | Erasca Inc | +3.6% | +37.18% | Add |
| 2 | 260 | Centessa Pharmaceuticals-adr | +2% | +133.12% | Add |
| 3 | ROIV | Roivant Sciences Ltd. | +1.9% | +64.71% | Add |
| 4 | XENE | Xenon Pharmaceuticals Inc | +1.8% | +34.00% | Add |
| 5 | ANAB | Anaptysbio Inc | +1.5% | +111.38% | Add |
| 6 | DNTH | Dianthus Therapeutics Inc | +1.5% | +247.83% | Add |
| 7 | STRO | Sutro Biopharma Inc | +0.9% | +42.91% | Add |
| 8 | ALKS | Alkermes plc | +0.9% | +35.00% | Add |
| 9 | COGT | Cogent Biosciences Inc | +0.8% | +114.29% | Add |
| 10 | ASND | Ascendis Pharma A/S | +0.8% | +216.67% | Add |
| 11 | SYRE | Spyre Therapeutics Inc | +0.7% | -10.71% | Trim |
| 12 | CATX | Perspective Therapeutics Inc | +0.6% | +954.86% | Add |
| 13 | OVID | Ovid Therapeutics Inc | +0.6% | +48.76% | Add |
| 14 | RVMD | Revolution Medicines Inc | +0.6% | +100.00% | Add |
| 15 | MDGL | Madrigal Pharmaceuticals Inc | +0.5% | +76.67% | Add |
| 16 | EPRX | Eupraxia Pharmaceuticals Inc | +0.5% | +429.67% | Add |
| 17 | ARWR | Arrowhead Pharmaceuticals In | +0.4% | +185.71% | Add |
| 18 | COGT 1.625 11-15-31Bond | Cogent Biosciences Inc | +0.4% | +600.00% | Add |
| 19 | BLTE | Belite Bio Inc - Adr | +0.4% | +225.00% | Add |
| 20 | APGE | Apogee Therapeutics Inc | +0.3% | +4.05% | Add |
| 21 | CLDX | Celldex Therapeutics Inc | +0.3% | +42.86% | Add |
| 22 | 430 | Terns Pharmaceuticals Inc | +0.3% | +2.30% | Add |
| 23 | ✓ | Zura Bio LTD | +0.3% | +41.39% | Add |
| 24 | CMPS | Compass Pathways PLC | +0.2% | +454.24% | Add |
| 25 | ACLXGBX | Arcellx Inc | +0.2% | -30.73% | Trim |
| 26 | AVR | Anteris Technologies Global | +0.1% | +87.47% | Add |
| 27 | PTGX | Protagonist Therapeutics Inc | +0.1% | — | Unchanged |
| 28 | IBIO | Ibio Inc | +0.1% | +51.04% | Add |
| 29 | AVBP | Arrivent Biopharma Inc | 0% | +16.67% | Add |
| 30 | MGNX | Macrogenics Inc | 0% | +3.24% | Add |
| 31 | CELC 2.75 08-01-31Bond | Celcuity Inc | 0% | — | Unchanged |
| 32 | 2KZ0 | Kezar Life Sciences Inc | 0% | — | Unchanged |
| 33 | QTTB | Q32 Bio Inc | — | — | Unchanged |
| 34 | XFOR | X4 Pharmaceuticals Inc | — | — | Unchanged |
| 35 | ADGM | Adagio Medical Holdings Inc | — | — | Unchanged |
| 36 | RCKTW | Rocket Pharmaceuticals In-27 | — | — | Unchanged |
| 37 | ✓ | 0% | — | Unchanged | |
| 38 | LENZ | Lenz Therapeutics Inc | 0% | — | Unchanged |
| 39 | OBIO | Orchestra Biomed Holdings In | -0.1% | -29.72% | Trim |
| 40 | CLYM | Climb Bio Inc | -0.1% | -46.15% | Trim |
| 41 | AVTX | Avalo Therapeutics Inc | -0.1% | +27.57% | Add |
| 42 | CRNX | Crinetics Pharmaceuticals In | -0.1% | — | Unchanged |
| 43 | ✓ | Proqr Therapeutics N.v. | -0.1% | — | Unchanged |
| 44 | NXTC | Nextcure Inc | -0.1% | -2.21% | Trim |
| 45 | ✓ | Newamsterdam Pharma Company | -0.1% | — | Unchanged |
| 46 | RZLT | Rezolute Inc | -0.1% | -34.17% | Trim |
| 47 | NAMS | NewAmsterdam Pharma Company N.V. | -0.1% | — | Unchanged |
| 48 | ✓ | Engene Holdings Inc | -0.1% | -5.13% | Trim |
| 49 | ORKA | Oruka Therapeutics Inc | -0.1% | -37.72% | Trim |
| 50 | VRCA | Verrica Pharmaceuticals Inc | -0.1% | — | Unchanged |
According to official SEC Form 13F filings, Affinity Asset Advisors, LLC reported a total U.S. public equity portfolio value of $2.2B across 103 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SPY, APGE, XENE) accounted for 22.6% of total reported equity market value during Q1 2026.
Top New Position Initiated
SPY
市值: $130.1M
Top Position Liquidated / Trimmed
XBI
前期市值: $182.9M
During Q1 2026, Affinity Asset Advisors, LLC's top holdings by market value included SPY (6.7%)、APGE (5.6%)、XENE (5.0%). The largest single position, SPY, represented 6.7% of total portfolio value.
In Q1 2026, Affinity Asset Advisors, LLC made 97 total portfolio adjustments, initiating 26 new buys, adding to 31 positions, trimming 25 holdings, and fully liquidating 15 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.